United Therapeutics Co. (NASDAQ:UTHR) Receives Average Recommendation of “Moderate Buy” from Brokerages

United Therapeutics Co. (NASDAQ:UTHR) has been given a consensus rating of “Moderate Buy” by the fourteen research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $357.17.

UTHR has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $400.00 price objective on shares of United Therapeutics in a research report on Thursday, August 1st. Oppenheimer boosted their price objective on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. UBS Group boosted their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. TD Cowen boosted their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Finally, Morgan Stanley downgraded shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $310.00 to $321.00 in a report on Thursday, July 11th.

United Therapeutics Stock Performance

Shares of UTHR opened at $358.53 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $366.08. The firm’s 50 day moving average price is $342.08 and its two-hundred day moving average price is $295.35. The firm has a market cap of $15.95 billion, a P/E ratio of 16.95, a PEG ratio of 1.29 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.24 EPS. On average, analysts forecast that United Therapeutics will post 24.84 EPS for the current fiscal year.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $320.45, for a total value of $1,153,620.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $41,658.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $320.45, for a total value of $1,153,620.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $41,658.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Raymond Dwek sold 5,000 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the sale, the director now directly owns 1,750 shares of the company’s stock, valued at approximately $569,362.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 111,252 shares of company stock valued at $36,939,427. 12.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of UTHR. Norges Bank bought a new stake in United Therapeutics during the fourth quarter worth about $100,519,000. PNC Financial Services Group Inc. lifted its holdings in shares of United Therapeutics by 6.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,636 shares of the biotechnology company’s stock worth $580,000 after acquiring an additional 164 shares during the last quarter. UBS Group AG lifted its holdings in shares of United Therapeutics by 12.2% in the fourth quarter. UBS Group AG now owns 64,674 shares of the biotechnology company’s stock worth $14,221,000 after acquiring an additional 7,020 shares during the last quarter. Corient Private Wealth LLC lifted its holdings in shares of United Therapeutics by 2.8% in the fourth quarter. Corient Private Wealth LLC now owns 17,036 shares of the biotechnology company’s stock worth $3,746,000 after acquiring an additional 461 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in shares of United Therapeutics by 355.8% in the fourth quarter. Franklin Resources Inc. now owns 49,851 shares of the biotechnology company’s stock worth $10,962,000 after acquiring an additional 38,915 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.